Journal
LumiMeds Review 2026: $125 Tirzepatide on a Prepaid Year, on the Thinnest Sourcing We Track
Released: Last reviewed:
Short answer — August 2026
LumiMeds advertises compounded tirzepatide at one twenty-five a month on a twelve-month plan billed as fifteen hundred dollars upfront, and one forty on a six-month plan — the lowest annualized tirzepatide figure on our August 2026 record — with no semaglutide product and no published month-to-month rate. The status line is the review's spine: reported, from a community-sourced capture, with our first-party checkout capture pending — the thinnest sourcing tier we publish, printed on the row precisely so a floor price doesn't borrow credibility it hasn't earned. The usual upfront-risk analysis for prepaid annual plans (see the head-to-head index) applies here with one amplifier: less is publicly confirmed.
The floor math, and the evidence gap
The arithmetic that makes the row matter: one twenty-five annualized beats bmiMD's monthly-billed one thirty-nine by one sixty-eight a year, at the cost of committing the full fifteen hundred on day one; the six-month rung (one forty, roughly eight forty committed) halves the concentration for fifteen more monthly. The gap that makes the row cautious: our record traces to a community-sourced figure — enough to record with labels, not enough to rank as confirmed — so the pre-payment diligence is heavier than usual: the enrollment confirmation stating rate, term, and total in writing; the refund clause verbatim; the pharmacy name (currently not in our records at all) plus the fifteen-minute verification; and a credit-card rail as the only payment method worth considering on an upfront year with thin public sourcing.
Verdict
If every advertised fact confirms at checkout, LumiMeds is a committed annual buyer's deal, clause-read and card-paid. If the funnel returns different numbers, the row corrects and the corrections log says so — which is exactly what our capture file exists to settle, and this row is its single highest-priority blank. Until one of those happens, treat the one twenty-five as what our label calls it: reported, pending, and priced like a floor precisely because floors attract both bargains and mirages.
Questions people ask
How much does LumiMeds cost?
Advertised: compounded tirzepatide at $125/month on a twelve-month plan billed $1,500 upfront, or $140/month on six months. No semaglutide, no month-to-month rate. Status: reported from a community-sourced capture, first-party verification pending — the thinnest sourcing tier we publish.
Is LumiMeds legit?
Unresolved is the honest answer our records support: the figures sit at the low end of our August 2026 tirzepatide record, and the public sourcing is thin (a community-surfaced capture pending our own). The diligence is therefore maximal: enrollment terms in writing, refund clause verbatim, pharmacy name plus license verification, credit-card payment only.
LumiMeds vs bmiMD — which annual plan is safer?
On the August 2026 record, bmiMD's $139 twelve-month tirzepatide tier billed monthly, so your exposure is one month at a time, while LumiMeds' $125 plan bills about $1,500 upfront on a single community-sourced capture. For $14 a month more, the monthly-billed shape is the safer one. Either way: read the refund clause as the price, verify the pharmacy, pay by card, and confirm current prices at checkout.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.